|
variable
|
Preeclampsia (n = 8)
|
Unaffected group (n = 254)
|
P value
|
|---|
|
Median gestational age (weeks)
|
11 (10–13)
|
11 (10–13)
|
0.651
|
|
PAPP-A, MoM
|
0.63 (0.34–1.67)
|
1.00 (0.20–3.85)
|
0.046
|
|
NT, MoM
|
1.05 (0.81–1.28)
|
1.00 (0.45–1.99)
|
0.724
|
|
Median gestational age
|
16 (15–17)
|
16 (14–18)
|
0.784
|
|
MSAFP, MoM
|
1.00 (0.41–4.38)
|
1.10 (0.55–2,96)
|
0.550
|
|
hCG,MoM
|
1.66 (1.16–2.68)
|
1.00 (0.20–6.53)
|
0.001
|
|
uE3, MoM
|
0.97 (0.69–1.28)
|
1.00 (0.46–1.83)
|
0.521
|
|
Inhibin A, MoM
|
1.86(0.82–2.96)
|
1.00 (0.39–3.676)
|
0.007
|
|
Median gestational age
|
26 (24–27)
|
27 (25–27)
|
0.378
|
|
sFlt-11, (pg/ml)
|
2360 (932–4435)
|
1296 (166–5710)
|
0.001
|
|
PlGF1, (pg/ml)
|
219 (34.25–698)
|
491 (91.37–2243)
|
0.016
|
|
sFlt-1/PlGF1
|
11.9 (1.7–70.9)
|
2.6 (0.3–12)
|
0.001
|
|
Median gestational age
|
34 (34–36)
|
36 (34–37)
|
<0.001
|
|
sFlt-12, (pg/ml)
|
6275 (4307–12835)
|
2334 (71.61–50475)
|
<0.001
|
|
PlGF2, (pg/ml)
|
115.9 (16.48–284.9)
|
287.95 (6.60–1749)
|
0.001
|
|
sFlt-1/PlGF2
|
76.3 (15.1–352.7)
|
8 (0.8–156)
|
<0.001
|
|
Uterine artery doppler
| | | |
|
Mean RI
|
0.55 (0.48–0.77)
|
0.57 (0.37–0.83)
|
0.972
|
|
Mean PI
|
0.94 (0.71–1.86)
|
0.97 (0.52–2.00)
|
0.949
|
|
Mean SD
|
2.25 (1.95–4.25)
|
2.35 (1.47–5.91)
|
0.913
|
|
Highest RI
|
0.58 (0.53–0.77)
|
0.62 (0.38–0.88)
|
0.526
|
|
Highest PI
|
1.03 (0.79–1.86)
|
1.06 (0.54–2.76)
|
0.808
|
|
Highest SD
|
2.40 (2.10–4.30)
|
2.58 (1.63–8.58)
|
0.642
|
|
Notch (%)
|
0.4
|
12.5
|
0.072
|
- Data are expressed as median (minimum–maximum).
- PAPP-A: pregnancy-associated plasma protein-A, NT: nuchal translucency thickness, MSAFP: alpha-fetoprotein, hCG: human chorionic gonadotropin, uE3: unconjugated estriol, sFlt-11: second trimester sFlt-1, PlGF1: second trimester PlGF, sFlt-1/PlGF1: second trimester sFlt-1/PlGF ratio, sFlt-12: third trimester sFlt-1, PlGF2: third trimester PlGF, sFlt-1/PlGF2: thirst trimester sFlt-1/PlGF ratio.
